These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25396298)

  • 1. Immune evasion in ebolavirus infections.
    Audet J; Kobinger GP
    Viral Immunol; 2015 Feb; 28(1):10-8. PubMed ID: 25396298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evasion of interferon responses by Ebola and Marburg viruses.
    Basler CF; Amarasinghe GK
    J Interferon Cytokine Res; 2009 Sep; 29(9):511-20. PubMed ID: 19694547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism.
    Seesuay W; Jittavisutthikul S; Sae-Lim N; Sookrung N; Sakolvaree Y; Chaicumpa W
    Emerg Microbes Infect; 2018 Mar; 7(1):41. PubMed ID: 29568066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.
    Kuzmin IV; Schwarz TM; Ilinykh PA; Jordan I; Ksiazek TG; Sachidanandam R; Basler CF; Bukreyev A
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
    Fanunza E; Frau A; Corona A; Tramontano E
    Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camouflage and misdirection: the full-on assault of ebola virus disease.
    Misasi J; Sullivan NJ
    Cell; 2014 Oct; 159(3):477-86. PubMed ID: 25417101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.
    Guito JC; Albariño CG; Chakrabarti AK; Towner JS
    Virology; 2017 Jan; 501():147-165. PubMed ID: 27930961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein.
    Pinski A; Woolsey C; Jankeel A; Cross R; Basler CF; Geisbert T; Messaoudi I
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.
    Ilinykh PA; Lubaki NM; Widen SG; Renn LA; Theisen TC; Rabin RL; Wood TG; Bukreyev A
    J Virol; 2015 Aug; 89(15):7567-83. PubMed ID: 25972536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.
    Schwarz TM; Edwards MR; Diederichs A; Alinger JB; Leung DW; Amarasinghe GK; Basler CF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27974555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
    Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filoviral immune evasion mechanisms.
    Ramanan P; Shabman RS; Brown CS; Amarasinghe GK; Basler CF; Leung DW
    Viruses; 2011 Sep; 3(9):1634-49. PubMed ID: 21994800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host Factors Involved in Ebola Virus Replication.
    Rasmussen AL
    Curr Top Microbiol Immunol; 2018; 419():113-150. PubMed ID: 28710692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ebolavirus VP35 is a multifunctional virulence factor.
    Leung DW; Prins KC; Basler CF; Amarasinghe GK
    Virulence; 2010; 1(6):526-31. PubMed ID: 21178490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
    Schirrmacher V
    Int J Mol Med; 2015 Jul; 36(1):3-10. PubMed ID: 25998621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on ebola virus glycoprotein].
    Ding GY; Wang ZY; Gao L; Jiang BF
    Bing Du Xue Bao; 2013 Mar; 29(2):233-7. PubMed ID: 23757858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate immune evasion by filoviruses.
    Basler CF
    Virology; 2015 May; 479-480():122-30. PubMed ID: 25843618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-λ1 gene expression.
    He F; Melén K; Maljanen S; Lundberg R; Jiang M; Österlund P; Kakkola L; Julkunen I
    Virology; 2017 Sep; 509():23-34. PubMed ID: 28595092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
    Wilson JA; Bray M; Bakken R; Hart MK
    Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.